down arrow

Soleno Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8342033094
USD
52.68
4.56 (9.49%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

49.9853.09

52 Week

41.5090.32
Valuation
Technical
Day's Volume

CASH

1.11 M

Shareholding (Mar 2025)

FII

13.04%

Held by 82 FIIs

DII

43.77%

Held by 33 DIIs

Promoter

16.43%

How big is Soleno Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Soleno Therapeutics, Inc. has a market capitalization of $3.91 billion, with net sales of $0.00 million and a net profit of -$198.22 million over the last four quarters. The company reported shareholder's funds of $245.11 million and total assets of $330.97 million as of Dec 24.

Market Cap: As of Jun 18, Soleno Therapeutics, Inc. has a market capitalization of 3,910.57 million, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Soleno Therapeutics reported net sales of 0.00 million and a net profit of -198.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 245.11 million and total assets of 330.97 million.

Read More

What does Soleno Therapeutics, Inc. do?

22-Jun-2025

Soleno Therapeutics, Inc. is a micro-cap healthcare company focused on developing and commercializing devices and diagnostics for neonatology. As of March 2025, it reported a net profit loss of $44 million and has a market cap of approximately $3.91 billion.

Overview:<BR>Soleno Therapeutics, Inc. is a healthcare company that develops and commercializes neonatology devices and diagnostics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -44 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,910.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -82.85% <BR>Price to Book: 16.84<BR><BR>Contact Details:<BR>Address: 1235 Radio Rd Ste 110, REDWOOD CITY CA: 94065-1217 <BR>Tel: 1 650 2138444 <BR>Fax: 1 302 6555049 <BR>Website: http://www.capnia.com

Read More

Who are in the management team of Soleno Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Soleno Therapeutics, Inc. includes Dr. Ernest Mario as the Independent Chairman and Dr. Anish Bhatnagar as the President and CEO, along with Independent Directors Mr. William Harris, Ms. Gwen Melincoff, Mr. Andrew Sinclair, and Dr. Birgitte Volck.

As of March 2022, the management team of Soleno Therapeutics, Inc. includes Dr. Ernest Mario as the Independent Chairman of the Board, Dr. Anish Bhatnagar as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Independent Directors Mr. William Harris, Ms. Gwen Melincoff, Mr. Andrew Sinclair, and Dr. Birgitte Volck.

Read More

Is Soleno Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 6, 2025, Soleno Therapeutics, Inc. is rated as risky due to its overvaluation, negative performance metrics, and a stock return of 5.66% over the past year, significantly underperforming the S&P 500's 17.14% return.

As of 6 August 2025, the valuation grade for Soleno Therapeutics, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its negative performance metrics, including a P/E ratio of NA due to losses, a Price to Book Value of 16.38, and a troubling ROE of -82.85%. <BR><BR>In comparison to its peers, Soleno's EV to EBITDA stands at -17.64, while Arcutis Biotherapeutics, Inc. and EyePoint Pharmaceuticals, Inc. have ratios of -24.8858 and -3.6610, respectively. This suggests that Soleno is not only underperforming relative to its industry but also faces significant challenges in generating positive returns. Notably, over the past year, Soleno's stock has returned 5.66%, significantly lagging behind the S&P 500's return of 17.14%, reinforcing the notion that the stock is overvalued in its current state.

Read More

Is Soleno Therapeutics, Inc. technically bullish or bearish?

22-Sep-2025

As of September 19, 2025, Soleno Therapeutics, Inc. shows a mildly bearish trend with mixed signals from various indicators, despite a year-to-date return of 21.78% that outperforms the S&P 500.

As of 19 September 2025, the technical trend for Soleno Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD remains bullish, indicating mixed signals across time frames. The Bollinger Bands are mildly bearish on the weekly and bearish on the monthly, supporting the bearish stance. Moving averages show a mildly bullish signal on the daily, but this is overshadowed by the overall bearish indicators from the KST, Dow Theory, and OBV, all of which are mildly bearish on both weekly and monthly charts. <BR><BR>In terms of performance, the stock has returned 21.78% year-to-date, outperforming the S&P 500's 13.31%, but has underperformed over the past month with a return of -18.07% compared to the S&P 500's 3.95%. Overall, the current technical stance is mildly bearish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of INF%, the company declared Very Positive results in Jun 25

  • The company has declared positive results in Jan 70 after 7 consecutive negative quarters
  • RAW MATERIAL COST(Y) Fallen by -9,787% (YoY)
  • NET SALES(9M) Higher at USD 32.66 MM
  • CASH AND EQV(HY) Highest at USD 576.79 MM
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,842 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

-73.21%

stock-summary
Price to Book

16.00

Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.3%
0%
-21.3%
6 Months
-31.93%
0%
-31.93%
1 Year
2.97%
0%
2.97%
2 Years
76.6%
0%
76.6%
3 Years
5064.71%
0%
5064.71%
4 Years
514.85%
0%
514.85%
5 Years
2643.75%
0%
2643.75%

Soleno Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Soleno Therapeutics Forms Death Cross, Signaling Potential Bearish Trend

Soleno Therapeutics Forms Death Cross, Signaling Potential Bearish Trend

Soleno Therapeutics, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Despite a strong performance over the past year, the stock is currently facing bearish indicators, with recent volatility contrasting broader market trends.

Read More
Soleno Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Fluctuations

Soleno Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Fluctuations

Soleno Therapeutics, Inc. has experienced notable stock fluctuations, with a recent closing price of 56.58. The company has shown strong short-term performance, outpacing the S&P 500, while facing challenges in the longer term. Technical indicators present mixed signals, reflecting the stock's volatility and market dynamics.

Read More

Is Soleno Therapeutics, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Soleno Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD remains bullish, indicating mixed signals across time frames. The Bollinger Bands are mildly bearish on the weekly and bearish on the monthly, supporting the bearish stance. Moving averages show a mildly bullish signal on the daily, but this is overshadowed by the overall bearish indicators from the KST, Dow Theory, and OBV, all of which are mildly bearish on both weekly and monthly charts. In terms of performance, the stock has returned 21.78% year-to-date, outperforming the S&P 500's 13.31%, but has underperformed over the past month with a return of -18.07% compared to the S&P 500's 3.95%. Overall, the current technical stance is mildly bearish....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
102.03%
EBIT Growth (5y)
-233.27%
EBIT to Interest (avg)
-54.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
16.38
EV to EBIT
-17.47
EV to EBITDA
-17.64
EV to Capital Employed
-491.42
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-82.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 52 Schemes (26.76%)

Foreign Institutions

Held by 82 Foreign Institutions (13.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 78.54% vs -157.65% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-22.70",
          "chgp": "78.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "-1.60",
          "chgp": "31.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-21.90",
          "chgp": "78.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-166.10%",
          "val2": "0.00%",
          "chgp": "-16.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -351.03% vs -61.83% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-182.40",
          "val2": "-36.70",
          "chgp": "-397.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.20",
          "val2": "-2.90",
          "chgp": "-10.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-175.90",
          "val2": "-39.00",
          "chgp": "-351.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
32.70
0.00
Operating Profit (PBDIT) excl Other Income
-4.90
-22.70
78.41%
Interest
1.40
0.00
Exceptional Items
-1.10
-1.60
31.25%
Consolidate Net Profit
-4.70
-21.90
78.54%
Operating Profit Margin (Excl OI)
-166.10%
0.00%
-16.61%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 78.54% vs -157.65% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-182.40
-36.70
-397.00%
Interest
0.20
0.00
Exceptional Items
-3.20
-2.90
-10.34%
Consolidate Net Profit
-175.90
-39.00
-351.03%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -351.03% vs -61.83% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Soleno Therapeutics, Inc. stock-summary
stock-summary
Soleno Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Company Coordinates stock-summary
Company Details
1235 Radio Rd Ste 110 , REDWOOD CITY CA : 94065-1217
stock-summary
Tel: 1 650 2138444
stock-summary
http://www.capnia.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."